Advertisement
Cancer Biology and Signal Transduction

Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression

Yuji Sano, Eri Hashimoto, Noriaki Nakatani, Masaichi Abe, Yasuko Satoh, Kiyoaki Sakata, Toshihiko Fujii, Kaori Fujimoto-Ouchi, Masamichi Sugimoto, Shigehisa Nagahashi, Masahiro Aoki, Hiroshi Motegi, Eiichi Sasaki and Yasushi Yatabe
DOI: 10.1158/1535-7163.MCT-14-0456 Published February 2015

Abstract

Erlotinib, a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI), benefits survival of patients with non–small cell lung cancer (NSCLC) who harbor activating EGFR mutations. However, elevated expression of hepatocyte growth factor (HGF), a ligand of the MET receptor tyrosine kinase, causes erlotinib resistance. Because onartuzumab, a monovalent antibody to MET, blocks HGF-induced MET activation, the addition of onartuzumab to erlotinib may improve therapeutic efficacy. We engineered the human NSCLC cell line PC-9 (MET-positive cells harboring an exon 19 deletion of EGFR) to overexpress hHGF and evaluated the effects of an onartuzumab and erlotinib combination in vitro and in vivo in xenograft models. A stable clone of PC-9/hHGF was less sensitive to erlotinib than the parental PC-9, and the addition of onartuzumab to erlotinib suppressed the proliferation of these cells in vitro. In PC-9/hHGF xenograft tumors, onartuzumab or erlotinib alone minimally inhibited tumor growth; however, combining onartuzumab and erlotinib markedly suppressed tumor growth. The total MET protein level was decreased in PC-9/hHGF cells, because MET is constitutively phosphorylated by autocrine HGF, leading to its ubiquitination and degradation. Onartuzumab reduced phospho-MET levels, inhibited MET ubiquitination, and consequently restored MET protein levels. Moreover, in NSCLC clinical specimens harboring activating EGFR mutations, more than 30% of patients expressed high levels of HGF. Our findings raised the possibility that patients with NSCLC with EGFR mutations who express high levels of HGF may benefit from onartuzumab and erlotinib combination therapy, and that HGF can be a novel biomarker for selecting such patients. Mol Cancer Ther; 14(2); 533–41. ©2014 AACR.

Introduction

Lung cancer, one of the leading causes of cancer-related mortality, is classified into two histologic subgroups: non–small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC; ref. 1). The treatment of NSCLC, which accounts for approximately 85% of lung cancer, has improved with the development of molecular targeted therapies (2). Tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR-TKI), such as erlotinib and gefitinib, are efficacious in patients with NSCLC with activating EGFR mutations (3–6). However, continuous administration of the drug decreases efficacy in once-responsive patients; the acquired EGFR T790M mutation, which causes resistance to EGFR-TKI, has been seen in half of these treatment-resistant patients (7–9). Some studies show that other than EGFR T790M, MET amplification and high expression of hepatocyte growth factor (HGF) also cause treatment resistance (10–13). High HGF expression levels in tumors, even in patients with activating EGFR mutations, are associated with a poor response to EGFR-TKI (14, 15) because the HGF–MET pathway, an alternative signaling route to EGFR, is also activated (16).

MET belongs to the receptor tyrosine kinase family. It was originally found as a fusion protein, TPR–MET, which was produced by translocation in a sarcoma cell line treated with a carcinogen (17). MET and its ligand, HGF, are known to regulate numerous biologic activities, including cell proliferation, migration, invasion, angiogenesis, survival, and metastasis (18–21). MET is highly expressed in various cancers (20), including NSCLC, and elevated MET and HGF levels in patients correlate with a higher pathologic tumor stage (22).

Unlike other anti-MET antibodies that may activate MET signaling (23, 24), onartuzumab was designed to be monovalent, to avoid agonistic activity (25), and it blocks the binding between MET and HGF (26, 27). Onartuzumab is produced in Escherichia coli and does not have antibody-dependent cellular cytotoxicity (ADCC; ref. 28). Demonstrating the ligand blocking activity of onartuzumab in xenograft models is problematic because mouse HGF does not activate human MET and thus has no effect on the proliferation of grafted human tumors (29, 30). Therefore, the only paracrine models available to date are those that supply human HGF via implanted osmotic pumps (26), by human HGF transgenic mice (31), or by the coinoculation of cancer cells with HGF-producing human fibroblast (32). However, onartuzumab has shown high efficacy in autocrine models that use the U-87MG and KP4 cell lines, which produce human HGF (26, 27).

In a phase II study of patients with second-line or third-line NSCLC, where most of the patients possess wild-type EGFR, erlotinib combined with onartuzumab improved progression-free survival (PFS) and overall survival (OS) in MET-positive patients, as determined by immunohistochemistry (IHC; refs. 33, 34). A phase III (MetLung) study was conducted with the same study design as the phase II study, where high HGF levels were not an inclusion criterion for patient selection. Interim analysis of the phase III data could not confirm the efficacy observed in the phase II study (35).

Here, we modified EGFR-mutated cell lines to overexpress human HGF, and observed the additive effect of onartuzumab and erlotinib on tumor growth inhibition. Our results suggested the possibility that the combination of onartuzumab and erlotinib may be more efficacious in patients with activating EGFR mutations who are erlotinib-resistant due to an elevated HGF expression.

Materials and Methods

Cell lines

PC-9, a human lung adenocarcinoma cell line harboring an activating EGFR mutation (deletion of E746–A750) was purchased from and characterized by Immuno-Biological Laboratories in 2009. HCC827, a human lung adenocarcinoma cell line with an activating EGFR mutation (deletion of E746–A750), and U-87MG, a glioblastoma cell line, were purchased from and characterized by the American Type Culture Collection in 2006 and 2005, respectively. KP4, a pancreatic cancer cell line, was purchased from and characterized by RIKEN Bio Resource Center in 2001. All cell lines were cultured according to suppliers' instructions. No further cell line authentication was conducted for all these cell lines.

Reagents

Erlotinib was obtained from Hoffmann–La Roche. Onartuzumab was obtained from Genentech, Inc. Gefitinib was purchased from Kemprotec. Crizotinib, a MET and ALK dual inhibitor, was prepared in-house.

Cell growth inhibition assay

Cells were plated in 96-well plates. After incubation for 1 day, various concentrations of erlotinib were added. For the combination assay, 30 μg/mL of onartuzumab was combined with various concentrations of erlotinib. To examine the effect of HGF on the sensitivity of PC-9 to erlotinib, 25 or 50 ng/mL of recombinant human HGF (R&D Systems) was used together with various concentrations of erlotinib. The cells were incubated for a further 3 days, and viable cells were counted by WST-8 assay (Dojindo Laboratories).

Establishment of stable PC-9/hHGF and HCC827/hHGF clones

We transfected human HGF expression plasmids into PC-9 or HCC827 cells by electroporation (Bio-Rad). Transfected cells were selected in medium containing 300 μg/mL of zeocin (Life Technologies), and resistant colonies were expanded. We detected human HGF in the culture medium of clones by enzyme-linked immunosorbent assay (ELISA) and selected one clone for PC-9, and two clones for HCC827 secreting a high level of HGF for further analysis.

Flow cytometric analysis

Cells were suspended in phosphate-buffered saline (PBS) with 0.5% bovine serum albumin (BSA). The anti-MET monoclonal antibody prepared in-house was added, and cells were then incubated on ice for 30 minutes. After washing with PBS containing 0.5% BSA, FITC-conjugated anti-mouse secondary antibody (Dako) was added. After washing with PBS containing 0.5% BSA, the samples were analyzed with Epics XL flow cytometer (Beckman–Coulter), or BD FACSVerse (Becton Dickinson) using the CellQuest Pro software (Becton Dickinson), or BD FACSuite software (Becton Dickinson). The antibody-binding capacity of the cell surface MET was calculated using a QIFI kit (Dako).

Western blotting

Cells were lysed with the cell lysis buffer [100 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 5 mmol/L EDTA, 10% glycerol, 1% Triton X-100). Tumor samples were homogenized with a multi-beads shocker cell disruptor (Yasui Kikai), or a Biomasher (Funakoshi). Protein concentration in the lysates was determined using the Bio-Rad Protein Assay (Bio-Rad), and 50 μg of total protein was resolved by SDS-PAGE. After transfer of proteins onto nitrocellulose membranes, the membranes were probed with specific antibodies against MET (Life Technologies), HGF (LifeSpan BioScience), EGFR (1005), beta-actin (C-2; Santa Cruz Biotechnology), phospho-EGFR (Y1068), phospho-MET (Y1234/1235), ERK, phospho-ERK (T202/Y204), AKT and phospho-AKT (S473), all from Cell Signaling Technology. After washing with Tris-buffered saline containing 0.05% Tween-20 (TBS-T), membranes were probed with species-specific IR-dye 680- or 800CW-conjugated secondary antibodies (LI-COR Bioscience). After washing with TBS-T, membranes were scanned and analyzed with an Odyssey infrared imaging system (LI-COR Bioscience).

Ubiquitination assay

Cells were treated with 50 μmol/L of MG132, a proteasome inhibitor (Sigma–Aldrich) and/or 30 μg/mL of onartuzumab for 12 hours. Cell lysate protein (800 μg) was used for immunoprecipitation with 1.2 μg of in-house–prepared anti-MET chimeric antibody (in which the Fc region was replaced with human Fc); immunoprecipitation proceeded on ice for 12 hours. After protein A sepharose was added to lysates, samples were rotated gently at 4°C for 2 hours. After extensive washing, immunoprecipitates were resolved by SDS-PAGE and proteins transferred onto nitrocellulose membranes. Ubiquitinated MET was detected by Western blotting using anti-ubiquitin Ab (P4D1; Santa Cruz Biotechnology).

Xenograft models

All animal studies were performed in accordance with the policies of the Institutional Animal Care and Use Committee (IACUC) of Chugai Pharmaceutical Co., Ltd. PC-9, PC-9/hHGF, HCC827, or HCC827/hHGF cells were inoculated subcutaneously into female nude mice. After tumors reached approximately 200 mm3 in volume, onartuzumab in PBS (30 mg/kg body weight, intraperitoneally, once) was administered alone or in combination with erlotinib in captisol (Cydex; 50 mg/kg body weight, orally, daily). Control animals received PBS and captisol as vehicle. Each group comprised 5 mice. Tumor volume was measured twice per week.

Quantitative reverse transcription polymerase chain reaction

For quantitative reverse transcription polymerase chain reaction (qRT-PCR), cultured cells and 124 NSCLC specimens, which were comprised of 123 adenocarcinomas and one squamous cell carcinoma, were examined. Total RNA was extracted from snap-frozen tissues using an RNeasy kit (Qiagen), and cDNAs were synthesized using a SuperScriptIII First-strand Synthesis System (Life Technologies). The synthesized cDNA was used for HGF, or MET qRT-PCR with SYBR Green (Life Technologies); levels were normalized to those of a housekeeping gene (GAPDH). Primer sequences were as follows: HGF forward: 5′-CTGCTCCCCATCGCCATCCCCTATG-3′, HGF reverse: 5′-TAGGGTAGTCTTTGCTGATTTTTG-3′, MET forward: 5′-CAGTGAGAAGGCTAAAGGAAACGAAAGATG-3′, MET reverse: 5′- GGACCGTCAAGAAGTAAATAAAATTGTTGC-3′, GAPDH 5′-forward: GTGAAGGTCGGAGTCAACG-3′, GAPDH reverse: 5′-TGAGGTCAATGAAGGGGTC-3′. PCR was performed on an ABI PRISM 7900HT system (Life Technologies) or ViiA7 real-time PCR system (Life Technologies), according to the manufacturers' instructions.

Immunohistochemical analysis

For immunohistochemical analysis of MET expression, we used a tissue microarray, which comprised a consecutive series of surgically resected lung cancer tissues, including 160 adenocarcinoma, 36 squamous cell carcinoma, 5 adenosquamous carcinoma, 4 small cell carcinoma, 4 large cell neuroendocrine carcinoma, 4 adenocarcinoma in situ, 4 large cell carcinoma, and 2 carcinoid tumor specimens. In this cohort, EGFR mutation status had already been assessed and has been reported (36). The sections were stained with anti-MET antibody (SP44; Ventana Medical Systems) using a Bench Mark XT system (Ventana) according to the manufacturer's protocol. MET expression was evaluated according to the criteria used in the onartuzumab clinical trials (33, 34).

This analysis, together with RT-PCR analysis of the clinical samples, formed part of a comprehensive lung cancer research program that had been approved by an institutional review board in the Aichi Cancer Center. Written informed consent for participation in the program was obtained from each patient.

Statistical analysis

All preclinical data were analyzed by the Student t test. For prevalence studies of MET-IHC and HGF qRT-PCR results, the χ2 test or Fisher exact test was used (two-tailed). P values < 0.05 were considered as statistically significant.

Results

Erlotinib sensitivity of PC-9 cells

PC-9 is a representative NSCLC cell line harboring a deletion of exon 19 of EGFR, and is well known to be particularly sensitive to EGFR-TKI (37). We confirmed that PC-9 is more sensitive than other NSCLC cell lines to erlotinib (Supplementary Fig. S1A). We also confirmed MET expression on the surface of PC-9 cells by flow cytometric analysis (Supplementary Fig. S1B).

Effect of HGF on erlotinib sensitivity of NSCLC cell lines

Next, we examined the effect of HGF on the erlotinib sensitivity of PC-9 cells. As shown in Fig. 1A, HGF addition reversed the efficacy of erlotinib in PC-9 cells in a dose-dependent manner. To further assess the effect of HGF on the phosphorylation status of downstream molecules in the HGF–MET pathway, we analyzed lysates of cells treated with erlotinib and/or HGF by Western blotting. Treatment of PC-9 cells with erlotinib decreased phospho-EGFR levels and subsequently decreased phospho-ERK and phospho-AKT levels. However, cotreatment of PC-9 cells with HGF and erlotinib reversed the effect of erlotinib, and restored phospho-ERK and phospho-AKT levels. Because the phospho-EGFR levels were still reduced and the phospho-MET levels were increased by this cotreatment, we assumed that activation of the HGF–MET pathway compensates for erlotinib-induced inhibition of the EGFR pathway (Fig. 1B).

Figure 1.
Figure 1.

HGF reverses the growth-inhibitory effect of erlotinib in PC-9 cells, an erlotinib-sensitive NSCLC cell line harboring an activating EGFR mutation. A, HGF lowered the sensitivity to erlotinib in PC-9 cells. Cells were treated with various concentrations of erlotinib with or without 20 or 50 ng/mL of recombinant human HGF for 3 days. Viable cells were counted by WST-8 assay (n = 3 wells; error bars, SD). B, HGF restored phospho-AKT (pAKT) and phospho-ERK (pERK) levels that were downregulated by erlotinib treatment. PC-9 cells were treated with 1 μmol/L of erlotinib and/or 50 ng/mL of HGF for 1 hour. Cell lysates were prepared, and phosphorylated protein levels were examined by Western blotting.

We examined the effect of HGF on erlotinib-sensitivity of HCC827 cells, another cell line harboring an activating EGFR mutation, to confirm that PC-9 is not the only cell line to show erlotinib resistance upon treatment with HGF. Similar results were obtained in HCC827 cells in growth inhibition and Western blotting assays (Supplementary Fig. S1C and S1D). We also examined the effect of HGF on erlotinib sensitivity of EGFR wild-type cell lines such as NCI-H292, NCI-H322, and Calu-3, which show relatively high sensitivity to erlotinib (Supplementary Fig. S1A). As shown in Supplementary Fig. S1E, HGF had a moderate effect on erlotinib resistance in these EGFR wild-type cells.

Establishment of PC-9/hHGF cell line

To establish both an intrinsic and an acquired EGFR-TKI resistance model, a human HGF expression plasmid was transfected into PC-9 cells. After zeocin selection, we performed HGF ELISA and detected increased HGF levels in the culture media of transfectants; one such clone (PC-9/hHGF) was chosen for further analysis (Supplementary Fig. S2A).

We then verified that the mature form of HGF was expressed in these cells by Western blotting (Fig. 2A).

Figure 2.
Figure 2.

Establishment of a stable PC-9 cell line expressing human HGF. A, PC-9 cells were transfected with a human HGF-expression vector. These PC-9/hHGF cells overexpressed mature human HGF, as detected by Western blotting. B, onartuzumab inhibited growth of PC-9/hHGF, but not PC-9 cells. Cells were treated with 30 μg/mL of onartuzumab for 3 days. Viable cells were counted with WST-8 assay, and growth inhibition activity was calculated (n = 6 wells; error bars, SD). C, increased growth-inhibitory effect of erlotinib in combination with onartuzumab in PC-9/hHGF cells. A constant concentration of onartuzumab (30 μg/mL) was combined with various concentrations of erlotinib and used for a growth inhibition assay in PC-9 and PC-9/hHGF (n = 3 wells; error bars, SD). D, MET-TKI in combination with erlotinib showed a synergistic effect on growth inhibition of PC-9/hHGF cells. Cells were treated with 1 μmol/L of crizotinib, a MET/ALK dual inhibitor (as a MET-TKI), and/or 1 μmol/L of erlotinib for 3 days. Viable cells were measured by WST-8, and growth inhibition was calculated (n = 4 wells; error bars, SD). E, combination of onartuzumab and erlotinib decreased phospho-AKT (pAKT) and phospho-ERK (pERK) levels in PC-9/hHGF cells. Cells were treated with 30 μg/mL of onartuzumab and/or 100 nmol/L of erlotinib for 6 hours. Cell lysates were prepared, and the phospho-AKT and phospho-ERK levels were detected by Western blotting.

EGFR-TKI sensitivity of PC9-/hHGF cells

We treated PC-9/hHGF cells with various concentrations of gefitinib or erlotinib to examine whether PC-9/hHGF showed resistance to EGFR-TKI. As expected, the sensitivity of PC-9/hHGF to EGFR-TKI was decreased compared with that of the PC-9 parent cells (Supplementary Fig. S2B).

Effect of onartuzumab and erlotinib on PC-9/hHGF cell proliferation

To confirm whether HGF overexpression renders PC-9 dependent upon HGF–MET signaling in addition to EGFR signaling, we examined the effect of onartuzumab on cell growth. Onartuzumab alone had no growth-inhibitory effect on PC-9 cells, but had a minimal effect on PC-9/hHGF cells (Fig. 2B).

Then, we investigated whether a combination of onartuzumab and erlotinib increased the growth-inhibitory effect of erlotinib. PC-9/hHGF cells were cotreated with various concentrations of erlotinib and 30 μg/mL of onartuzumab. When combined with onartuzumab, erlotinib showed increased growth inhibition of PC-9/hHGF cells, compared with the effects of onartuzumab alone (25%–30% growth inhibition; Fig. 2C). Next, we cotreated PC-9/hHGF cells with various concentrations of onartuzumab and 1 μmol/L of erlotinib and also found increased growth inhibition compared with the effect of erlotinib alone (20% growth inhibition; Supplementary Fig. S2C). Similar results were obtained when replacing onartuzumab with crizotinib, a MET/ALK-TKI that interferes with the MET–HGF pathway (Fig. 2D, Supplementary Fig. S2D). We also established HGF-overexpressing clones of HCC827 cells and confirmed the high HGF expression level by qRT-PCR (Supplementary Fig. S2E). We examined whether the combination of onartuzumab and erlotinib increased growth inhibition of HCC827/hHGF cells and found the same results as for PC-9/hHGF cells (Supplementary Fig. S2F). These results indicated that autocrine HGF overexpression contributes to EGFR-TKI resistance in cells harboring activating EGFR mutations (Fig. 2B–2D and Supplementary Fig. S2B–S2D and S2F).

Effect of onartuzumab and erlotinib on phosphorylation of AKT and ERK

To confirm this additive effect of onartuzumab and erlotinib, we analyzed the phosphorylation status of signaling molecules in cells treated with onartuzumab and/or erlotinib by Western blotting. In PC-9 cells, treatment with erlotinib alone caused a significant reduction of both phospho-AKT and phospho-ERK levels, but onartuzumab alone had no impact on the phosphorylation status of these molecules, and combining onartuzumab with erlotinib caused no further reduction. On the other hand, in PC-9/hHGF cells, erlotinib treatment could not reduce phospho-AKT or phospho-ERK levels as much as it could in PC-9 cells, whereas a combination of the two drugs resulted in an additive or synergistic effect on phospho-AKT and phospho-ERK reduction (Fig. 2E).

Effects of onartuzumab and erlotinib in xenograft models

Next, we examined the in vivo efficacy of the combination of onartuzumab and erlotinib. We confirmed that HGF levels in the sera of PC-9/hHGF-engrafted mice whose tumor size was around 200 mm3 were comparable with those of HGF-high patients in the onartuzumab phase I study (Supplementary Fig. S3A; ref. 38). Consistent with the in vitro data, erlotinib, but not onartuzumab, showed strong growth inhibition of xenograft tumors derived from the parent PC-9 line (Fig. 3A). On the other hand, erlotinib was less efficacious in PC-9/hHGF xenograft models than in PC-9 models, and onartuzumab demonstrated minimal effects. However, a combination of the two drugs significantly increased the efficacy of tumor growth inhibition (Fig. 3B). Similar results were obtained in the HCC827 and HCC827/hHGF clone 9 xenograft model (Fig. 3C and D). Surprisingly, the efficacy of the drug combination in the PC-9/hHGF xenograft model lasted for more than 100 days, showing that the onartuzumab and erlotinib combination has a marked and durable effect (Supplementary Fig. S3B).

Figure 3.
Figure 3.

In vivo efficacy of onartuzumab and erlotinib combination in xenograft models. A, adding onartuzumab to erlotinib did not increase therapeutic efficacy in a PC-9 xenograft model. Onartuzumab was administered at 30 mg/kg body weight intraperitoneally by injection once. Erlotinib was administered daily at 50 mg/kg orally (n = 5 mice in each group; error bars, SD). B, additive efficacy of combination therapy in the PC-9/hHGF xenograft model. Dosing and administration schedule were the same as described for the PC-9 xenograft model (n = 5 mice per group; error bars, SD). C, absence of an additive efficacy of combination therapy in the HCC827 xenograft model. Dosing and administration schedule were as described for the PC-9 xenograft model (n = 5; error bars, SD). D, additive efficacy of combination therapy in the HCC827/hHGF clone 9 xenograft model. Dosing and administration schedule were as described for the PC-9 xenograft model (n = 5; error bars, SD).

We also examined the phosphorylation status of downstream molecules in PC-9/hHGF tumors and found that the combination of onartuzumab and erlotinib decreased phospho-ERK and phospho-AKT levels more than the administration of the single drugs did (Supplementary Fig. S3C). We also performed Ki-67 immunostaining in formalin-fixed paraffin-embedded (FFPE) xenograft tumor tissue sections and confirmed the combination effect (Supplementary Fig. S3D). Thus, we concluded that both onartuzumab and erlotinib are required to inhibit the proliferation of PC-9/hHGF and HCC827/hHGF tumors (Supplementary Fig S3E).

MET expression in Japanese lung cancer patients with activating EGFR mutations

To assess the ratio of MET-positive Japanese NSCLC patients with activating EGFR mutations, we performed MET-IHC on their FFPE lung cancer tissue sections, using the same method and scoring system as in the onartuzumab clinical trials (Table 1, Supplementary Fig. S4). According to an onartuzumab phase II clinical trial that was conducted mainly in the United States, MET-IHC diagnostic positivity, which is defined as a score of 2+ and 3+, was estimated to be around 50% in patients with NSCLC (34). However, in our study, 23.2% of Japanese patients were found to be MET-positive (Table 1), a discrepancy that may be associated with ethnic differences. Interestingly, 35.4% of patients with lung cancer with EGFR mutations were found to be MET-positive, as compared with 15.5% of patients without EGFR mutations. This result implied that the activation of the EGFR pathway might be involved in inducing MET transcription and/or stabilizing the MET protein.

View this table:
Table 1.

MET-diagnostic positive ratio in Japanese lung cancer patients

MET levels in PC-9/hHGF

We were surprised to observe that MET protein levels in the HGF-transfected cells were less than in the parent cells for both PC-9 and HCC827 cell lines (Fig. 4A). Moreover, the decreased MET levels recovered upon treatment of PC-9/hHGF with onartuzumab or MET-TKI, even though phospho-MET levels were reduced (Fig. 2E, Supplementary Fig. S5A). Taken together, this indicated that HGF overexpression stimulates MET downregulation as well as cell proliferation.

Figure 4.
Figure 4.

Overexpression of HGF decreases MET protein levels. A, MET protein levels were decreased in HGF-overexpressing clones compared with the parent cells. Cell lysates of PC-9, PC-9/hHGF, HCC827, and HCC827/hHGF cells were prepared and total MET expression levels then detected by Western blotting. B, MET protein levels at the cell surface were increased by onartuzumab treatment. PC-9 and PC-9/hHGF cells were treated with 30 μg/mL of onartuzumab for 6 and 24 hours. After cells were collected, 30 μg/mL of anti-MET mouse monoclonal antibody, recognizing a different epitope to onartuzumab, was added. An FITC-conjugated anti-mouse IgG was used as a secondary antibody. Cell surface MET levels were analyzed by flow cytometry. Red line, mock control; green line, untreated cells; pink line, onartuzumab-treated cells. C, MET protein levels in PC-9/hHGF tumors were increased by onartuzumab treatment. Six mice bearing PC-9/hHGF xenograft tumors were administered onartuzumab (30 mg/kg body weight) for 24 hours and 50 mg/kg of erlotinib for 6 hours. Mice were sacrificed, and tumor lysates were used for Western blotting of MET. MET protein level was quantified by densitometry analysis of Western blotting bands. *, P < 0.05. D, onartuzumab inhibits MET ubiquitination. Cells were treated with 50 μmol/L of MG-132, a proteasome inhibitor, in the presence or absence of 30 μg/mL of onartuzumab. Cell lysates were prepared and then immunoprecipitated with 1.2 μg/mL of anti-MET antibody. Ubiquitinated MET was detected by Western blotting using an anti-ubiquitin antibody. E, onartuzumab restored total MET protein levels in U-87MG and KP4 cells, which are HGF autocrine cells. U-87MG and KP4 cells were treated with 30 μg/mL of onartuzumab for 6, 12, or 24 hours; cell lysates were prepared and the total MET protein levels were examined by Western blotting. F, MET mRNA levels were analyzed by qRT-PCR in U-87MG and KP4 cells that had been treated with onartuzumab. U-87MG and KP4 cells were treated with 30 μg/mL of onartuzumab for 24 hours, and MET mRNA levels determined by qRT-PCR and normalized to GAPDH mRNA levels (n = 3 wells; error bars, SD). G, autocrine HGF activated both cell proliferation and MET-degradation signals.

We also examined the change in MET levels at the cell surface by flow cytometric analysis. In PC-9 cells, onartuzumab treatment did not shift the MET peak, but in the PC-9/hHGF cells, onartuzumab treatment resulted in a shift of the MET peak (Fig. 4B). Similar results were obtained with MET flow cytometric analysis when PC-9 parent cells were treated with recombinant HGF in the presence of onartuzumab (Supplementary Fig. S5B). We confirmed that onartuzumab administration resulted in increased MET protein levels as quantified by densitometric analysis of Western blots of proteins obtained from a PC-9/hHGF xenograft model (Fig. 4C). On the basis of these results, we speculated that when onartuzumab reduces the phospho-MET level, MET is no longer recognized by Cbl, a ubiquitin ligase of MET, and escapes from ubiquitin-dependent degradation.

To prove this hypothesis, we examined the effect of onartuzumab on MET ubiquitination. We treated cells with MG-132, a proteasome inhibitor, with or without onartuzumab. Cell lysates were immunoprecipitated using an anti-MET antibody, and ubiquitinated MET was then detected with an anti-ubiquitin antibody on Western blots. As shown in Fig. 4D, MET was ubiquitinated in the presence of MG132 in PC-9/hHGF cells; however, its level was decreased by onartuzumab treatment, suggesting that inhibition of MET-ubiquitination by onartuzumab treatment causes recovery of the total MET level.

MET levels in other HGF-autocrine cell lines

Next, we also investigated whether this event was observed in native cancer cell lines. We selected U-87MG and KP4 cells, both of which are well known for overexpressing HGF; onartuzumab has also been shown to have strong growth-inhibition activity in xenograft tumors derived from these cell lines (26, 27). Similar to our findings in PC-9/hHGF cells, MET protein levels were increased by onartuzumab treatment in U87-MG and KP4, although phospho-MET levels were decreased (Fig. 4E). The difference in MET protein levels did not derive from the transcriptional level, as no significant changes in mRNA levels were observed between the control and the onartuzumab-treated samples (Fig. 4F). We also obtained similar results when we used a MET-TKI or HGF siRNA instead of onartuzumab to inhibit MET–HGF activation (Supplementary Fig. S5C and S5D). We also confirmed that HGF siRNA significantly inhibited proliferation of U-87MG and KP4 cells (Supplementary Fig. S5E).

By screening lung cancer cell lines with HGF qRT-PCR, we found that HCC2108 expressed high levels of endogenous HGF (Supplementary Fig. S6A), and the proliferation of HCC2108 was inhibited by HGF siRNA, suggesting that the proliferation depends on HGF (Supplementary Fig. S6B). Next, we treated HCC2108 cells with onartuzumab or crizotinib to observe the changes in MET protein levels. As expected, treatment with onartuzumab or crizotinib resulted in increased MET protein levels (Supplementary Fig. S6C) without significant changes in the mRNA levels (Supplementary Fig. S6D). We therefore concluded that the MET degradation pathway is activated, in addition to activation of a proliferation signal, in most HGF-autocrine cells (Fig. 4G).

HGF mRNA levels in NSCLC specimens

We then performed HGF qRT-PCR using NSCLC clinical samples. Of NSCLC patients with activating EGFR mutations, 34.4% (21 of 61) expressed HGF levels higher than that seen in U-87MG cells, in which tumor growth was regressed by treatment with more than 7.5 mg/kg onartuzumab (28), suggesting that HGF levels in U-87MG cells are sufficient for onartuzumab to be highly effective. These 34.4% patients with NSCLC with high levels of HGF and activating EGFR mutations may not respond well to erlotinib monotherapy, but a combination of onartuzumab and erlotinib may be more efficacious in these patients.

Discussion

Several studies have confirmed the efficacy of erlotinib and gefitinib in patients with NSCLC with activating EGFR mutations (39–41); therefore, these drugs have been approved for use as first-line treatment. However, not all patients with activating EGFR mutations respond to erlotinib, indicating that activating EGFR mutation is not the sole factor affecting erlotinib sensitivity.

Yano and colleagues observed that about 29% (13 of 45) of patients who did not respond to EGFR-TKI despite having EGFR mutations showed high HGF expression in their tumors (15). Several reports have also shown that high HGF expression is associated with acquired and intrinsic resistance to EGFR-TKI (13, 15, 16). We here confirmed that activation of MET signaling by HGF overexpression causes EGFR-TKI resistance in PC-9/hHGF cells. Because both MET–HGF and EGFR pathways are simultaneously stimulated in PC-9/hHGF cells, neither a MET inhibitor nor an EGFR inhibitor alone was sufficient to completely inhibit cell growth. Thus, blocking both EGFR and MET–HGF pathways is required for complete inhibition of cell growth (Supplementary Fig. S3E). Because mouse HGF does not activate human MET, we used the HGF-autocrine model in vivo. Similar results in a paracrine model in PC-9 coinoculated with HGF-producing human fibroblasts have been reported (32).

We analyzed the HGF expression levels by qRT-PCR in frozen NSCLC surgical specimens. Consistent with the report of Yano and colleagues (15), high expression of HGF was observed in 34% (21 of 61) of patients with exon 19 deletion and the L858R mutation in EGFR. Interestingly, the HGF-high ratio (HGF-high was defined as higher HGF expression than that in U-87MG cells) in EGFR-mutated patients was higher than that seen in EGFR WT patients (19%; 10 of 52), although this difference was not statistically significant (P = 0.0913; Table 2). As well as HGF, the MET-diagnostic positive ratio is higher in EGFR-mutated patients than in EGFR WT patients by IHC (P = 0.00135; Table 1). Although the precise mechanisms have not been elucidated, EGFR signaling, activated by a mutation, may enhance MET–HGF transcription or protein stability. We also found that erlotinib decreased not only phospho-EGFR, but also phospho-MET in PC-9 and PC-9/hHGF cells (Fig. 2E), suggesting that mutated EGFR trans-activates MET signaling. These results imply a rationale for MET and EGFR combination therapy in NSCLC.

View this table:
Table 2.

High positive ratio of HGF in Japanese lung cancer patients

In the ongoing MetDriver study, which is a phase III clinical trial using a combination of erlotinib and onartuzumab, or erlotinib alone, as first-line treatment in patients with NSCLC with activating EGFR mutations, MET expression status was tested by IHC, and only MET-diagnostic positive patients (MET-IHC scores of 2+ and 3+) were included; however, HGF-high patients were not prospectively selected (ClinicalTrial.gov, NCT01887886). In our PC-9/hHGF model, the combined use of onartuzumab and erlotinib showed high efficacy, despite the low MET expression levels. In addition, onartuzumab showed high efficacy in U-87MG and KP4 cells, in which elevated HGF levels resulted in decreased MET protein levels. We also observed that MET protein levels in HGF-autocrine cells, including PC-9/hHGF, U-87MG, and KP4 cells, were less than in A549 or HOP-92 cells, representative cell lines with MET-IHC scores of +2 (Supplementary Fig. S7). We demonstrated that autocrine HGF activates not only proliferation but also MET downregulation via the ubiquitin-proteasome pathway, in which Cbl triggers ubiquitination and degradation of MET by binding to phospho-MET (42, 43). These data suggested that measuring HGF expression levels in addition to MET-IHC may be important for selecting patients who are likely to benefit from combination therapy. Although the small sample number confounded the correlation between blood HGF levels and survival rate in the phase II trial of onartuzumab and erlotinib (38), it is likely that high HGF levels, not in the blood, but in the tumor region, can be a novel biomarker for onartuzumab use in future.

In conclusion, we showed that the combined use of onartuzumab and erlotinib has an additive effect in a model that expresses high levels of human HGF in cells with an activating EGFR mutation. This suggests that the use of a combination of onartuzumab and erlotinib may achieve higher efficacy in the first-line treatment of patients with NSCLC with activating EGFR mutations and high levels of HGF expression.

Disclosure of Potential Conflicts of Interest

Y. Yatabe has speakers' bureau honoraria from Chugai Pharmaceuticals Co., Ltd. and Ventana Roche and is a consultant/advisory board member for Ventana Roche. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: Y. Sano, E. Hashimoto, N. Nakatani, M. Abe, Y. Yatabe

Development of methodology: Y. Sano, N. Nakatani, Y. Satoh, Y. Yatabe

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Y. Sano, E. Hashimoto, N. Nakatani, Y. Yatabe

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Y. Sano, E. Hashimoto, N. Nakatani, K. Sakata, T. Fujii, M. Sugimoto, H. Motegi, E. Sasaki, Y. Yatabe

Writing, review, and/or revision of the manuscript: Y. Sano, E. Hashimoto, N. Nakatani, K. Fujimoto-Ouchi, M. Sugimoto, H. Motegi, Y. Yatabe

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Y. Sano, E. Hashimoto, Y. Yatabe

Study supervision: Y. Sano, N. Nakatani, K. Fujimoto-Ouchi, M. Sugimoto, S. Nagahashi, M. Aoki, Y. Yatabe

Grant Support

This study was funded by Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Acknowledgments

The authors thank Robin G. Taylor, Ellen Filvaroff, Mark Merchant, Dale Dei Rossi, and See Phan from Genentech, Inc., for their support, advice on this study, and in preparing this article. The authors also thank Ikuko Matsuo, Asuka Motoda, and Yumiko Hashimoto from Chugai Pharmaceutical Co., Ltd., for assistance with in vitro experiments.

Footnotes

  • Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

  • Received June 5, 2014.
  • Revision received November 17, 2014.
  • Accepted December 2, 2014.

References

  1. 1.↵
    1. Jemal A,
    2. Bray F,
    3. Center MM,
    4. Ferlay J,
    5. Ward E,
    6. Forman D
    . Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Oxnard GR,
    2. Binder A,
    3. Janne PA
    . New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 2013;31:1097–104.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Siegfried JM,
    2. Weissfeld LA,
    3. Singh-Kaw P,
    4. Weyant RJ,
    5. Testa JR,
    6. Landreneau RJ
    . Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res 1997;57:433–9.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Paez JG,
    2. Janne PA,
    3. Lee JC,
    4. Tracy S,
    5. Greulich H,
    6. Gabriel S,
    7. et al.
    EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497–500.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Pao W,
    2. Miller V,
    3. Zakowski M,
    4. Doherty J,
    5. Politi K,
    6. Sarkaria I,
    7. et al.
    EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306–11.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Lynch TJ,
    2. Bell DW,
    3. Sordella R,
    4. Gurubhagavatula S,
    5. Okimoto RA,
    6. Brannigan BW,
    7. et al.
    Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–39.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Kobayashi S,
    2. Boggon TJ,
    3. Dayaram T,
    4. Jänne PA,
    5. Kocher O,
    6. Meyerson M,
    7. et al.
    EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786–92.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Pao W,
    2. Miller VA,
    3. Politi KA,
    4. Riely GJ,
    5. Somwar R,
    6. Zakowski MF,
    7. et al.
    Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Yun CH,
    2. Mengwasser KE,
    3. Toms AV,
    4. Woo MS,
    5. Greulich H,
    6. Wong KK,
    7. et al.
    The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008;105:2070–5.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Ma C,
    2. Wei S,
    3. Song Y
    . T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis 2011;3:10–8.
    OpenUrlPubMed
  11. 11.↵
    1. Engelman JA,
    2. Zejnullahu K,
    3. Mitsudomi T,
    4. Song Y,
    5. Hyland C,
    6. Park JO,
    7. et al.
    MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039–43.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Bean J,
    2. Brennan C,
    3. Shih JY,
    4. Riely G,
    5. Viale A,
    6. Wang L,
    7. et al.
    MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932–7.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Turke AB,
    2. Zejnullahu K,
    3. Wu YL,
    4. Song Y,
    5. Dias-Santagata D,
    6. Lifshits E,
    7. et al.
    Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010;17:77–88.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Suda K,
    2. Murakami I,
    3. Katayama T,
    4. Tomizawa K,
    5. Osada H,
    6. Sekido Y,
    7. et al.
    Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010;16:5489–98.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Yano S,
    2. Yamada T,
    3. Takeuchi S,
    4. Tachibana K,
    5. Minami Y,
    6. Yatabe Y,
    7. et al.
    Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 2011;6:2011–7.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Yano S,
    2. Wang W,
    3. Li Q,
    4. Matsumoto K,
    5. Sakurama H,
    6. Nakamura T,
    7. et al.
    Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008;68:9479–87.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Cooper CS,
    2. Park M,
    3. Blair DG,
    4. Tainsky MA,
    5. Huebner K,
    6. Croce CM,
    7. et al.
    Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984;311:29–33.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Goetsch L,
    2. Caussanel V,
    3. Corvaia N
    . Biological significance and targeting of c-Met tyrosine kinase receptor in cancer. Front Biosci 2013;18:454–73.
    OpenUrlCrossRef
  19. 19.↵
    1. Birchmeier C,
    2. Gherardi E
    . Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 1998;8:404–10.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Birchmeier C,
    2. Birchmeier W,
    3. Gherardi E,
    4. Vande Woude GF
    . Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915–25.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Liu X,
    2. Yao W,
    3. Newton RC,
    4. Scherle PA
    . Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 2008;17:997–1011.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Olivero M,
    2. Rizzo M,
    3. Madeddu R,
    4. Casadio C,
    5. Pennacchietti S,
    6. Nicotra MR,
    7. et al.
    Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 1996;74:1862–8.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Prat M,
    2. Crepaldi T,
    3. Pennacchietti S,
    4. Bussolino F,
    5. Comoglio PM
    . Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci 1998;111:237–47.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Petrelli A,
    2. Circosta P,
    3. Granziero L,
    4. Mazzone M,
    5. Pisacane A,
    6. Fenoglio S,
    7. et al.
    Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci U S A 2006;103:5090–5.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Nguyen TH,
    2. Loux N,
    3. Dagher I,
    4. Vons C,
    5. Carey K,
    6. Briand P,
    7. et al.
    Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment antibody against c-Met. Cancer Gene Ther 2003;10:840–9.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Jin H,
    2. Yang R,
    3. Zheng Z,
    4. Romero M,
    5. Ross J,
    6. Bou-Reslan H,
    7. et al.
    MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008;68:4360–8.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Martens T,
    2. Schmidt NO,
    3. Eckerich C,
    4. Fillbrandt R,
    5. Merchant M,
    6. Schwall R,
    7. et al.
    A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006;12:6144–52.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Merchant M,
    2. Ma X,
    3. Maun HR,
    4. Zheng Z,
    5. Peng J,
    6. Romero M,
    7. et al.
    Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A 2013;110:E2987–96.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Bhargava M,
    2. Joseph A,
    3. Knesel J,
    4. Halaban R,
    5. Li Y,
    6. Pang S,
    7. et al.
    Scatter factor and hepatocyte growth factor: activities, properties, and mechanism. Cell Growth Differ 1992;3:11–20.
    OpenUrlAbstract
  30. 30.↵
    1. Rong S,
    2. Bodescot M,
    3. Blair D,
    4. Dunn J,
    5. Nakamura T,
    6. Mizuno K,
    7. et al.
    Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 1992;12:5152–8.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Merchant M,
    2. Zheng Z,
    3. Su Y,
    4. Romero M,
    5. Louie S,
    6. Severin C,
    7. et al.
    Combination efficacy with MetMAb and erlotinib ina NSCLC tumor model highlight therapeutic opportunities for a-Met inhibitors in combination with EGFR inhibitors. AACR Meeting Abstracts 2008;1336.
  32. 32.↵
    1. Wang W,
    2. Li Q,
    3. Yamada T,
    4. Matsumoto K,
    5. Matsumoto I,
    6. Oda M,
    7. et al.
    Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2009;15:6630–8.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Spigel DR,
    2. Ervin TJ,
    3. Ramlau RA,
    4. Daniel DB,
    5. Goldschmidt JH Jr.,
    6. Blumenschein GR Jr.,
    7. et al.
    Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013;31:4105–14.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Yu W,
    2. Pandita A,
    3. Penuel E,
    4. Raja R,
    5. Zha J,
    6. Mohan S,
    7. et al.
    Exploratory biomarker nalysis from OAM4558g: A placebo-controlled phase II study of erlotinib +MetMAb in patients with advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 2011;29 (suppl; abstr 7529).
  35. 35.↵
    1. Spigel DR,
    2. Edelman MJ,
    3. O'Byrne K,
    4. Paz-Ares L,
    5. Shames DS,
    6. Yu W,
    7. et al.
    Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol 2014;32:5s (Suppl; Abstr 8000).
    OpenUrlCrossRef
  36. 36.↵
    1. Mitsudomi T,
    2. Kosaka T,
    3. Endoh H,
    4. Horio Y,
    5. Hida T,
    6. Mori S,
    7. et al.
    Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513–20.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Ogino A,
    2. Kitao H,
    3. Hirano S,
    4. Uchida A,
    5. Ishiai M,
    6. Kozuki T,
    7. et al.
    Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res 2007;67:7807–14.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Penuel E,
    2. Li C,
    3. Parab V,
    4. Burton L,
    5. Cowan KJ,
    6. Merchant M,
    7. et al.
    HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors. Mol Cancer Ther 2013;12:1122–30.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Zhou C,
    2. Wu YL,
    3. Chen G,
    4. Feng J,
    5. Liu XQ,
    6. Wang C,
    7. et al.
    Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735–42.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Wu YL,
    2. Fukuoka M,
    3. Mok TS,
    4. Saijo N,
    5. Thongprasert S,
    6. Yang JC,
    7. et al.
    Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study. Lung Cancer 2013;81:280–7.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Saijo N,
    2. Takeuchi M,
    3. Kunitoh H
    . Reasons for response differences seen in the V15–32, INTEREST and IPASS trials. Nat Rev Clin Oncol 2009;6:287–94.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Taher TE,
    2. Tjin EP,
    3. Beuling EA,
    4. Borst J,
    5. Spaargaren M,
    6. Pals ST
    . c-Cbl is involved in Met signaling in B cells and mediates hepatocyte growth factor-induced receptor ubiquitination. J Immunol 2002;169:3793–800.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Lai AZ,
    2. Durrant M,
    3. Zuo D,
    4. Ratcliffe CD,
    5. Park M
    . Met kinase-dependent loss of the E3 ligase Cbl in gastric cancer. J Biol Chem 2012;287:8048–59.
    OpenUrlAbstract/FREE Full Text
Back to top
Molecular Cancer Therapeutics: 14 (2)
February 2015
Volume 14, Issue 2

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Email Article
Citation Tools
Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
Yuji Sano, Eri Hashimoto, Noriaki Nakatani, Masaichi Abe, Yasuko Satoh, Kiyoaki Sakata, Toshihiko Fujii, Kaori Fujimoto-Ouchi, Masamichi Sugimoto, Shigehisa Nagahashi, Masahiro Aoki, Hiroshi Motegi, Eiichi Sasaki and Yasushi Yatabe
Mol Cancer Ther February 1 2015 (14) (2) 533-541; DOI: 10.1158/1535-7163.MCT-14-0456
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement